Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07104396 · ClinicalTrials.gov registry record

Cogito: A Turnkey Solution for Rapidly Developing, Evaluating, Deploying, and Scaling Digital Therapeutics

A clinical trial of Substance Use Disorders (SUDs), sponsored by Square2 Systems.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT07104396: Recruiting study of Substance Use Disorders (SUDs), sponsored by Square2 Systems.

NCT07104396 is a study of Substance Use Disorders (SUDs) that is actively recruiting participants, run by Square2 Systems. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07104396, a study of Substance Use Disorders (SUDs), is actively recruiting participants, sponsored by Square2 Systems.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

This is a research study to evaluate the usability of the Cogito digital therapeutics development platform. The Cogito platform is designed to allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide the components for building a digital therapeutic for any health condition and population. And in this initial study, the research team plans to examine the usability of Cogito in building a digital therapeutic for substance use disorders (SUDs).

Primary Outcome

Each participant will be asked to complete the standardized 10-item System Usability Scale (SUS) to evaluate the usability of Cogito (e.g., "I think I would like to use this system frequently"), ranging from "strongly agree" to "strongly disagree".

Interventions

  • OTHER Cogito digital therapeutics development platform

Study Locations (1)

New Hampshire

  • Square 2 Systems - Hanover

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-07-02
Est. Completion 2025-08-31
Square2 Systems

2 total trials

What NCT07104396 shows while recruiting

NCT07104396 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.

The record links to 1 condition, with Substance Use Disorders (SUDs) appearing as the primary indexed condition, and to 1 intervention - of which Cogito digital therapeutics development platform is the first listed.

NCT07104396 reports a single indexed study location in New Hampshire.

Frequently Asked Questions

What is clinical trial NCT07104396 about?

NCT07104396 is a clinical study titled "Cogito: A Turnkey Solution for Rapidly Developing, Evaluating, Deploying, and Scaling Digital Therapeutics". This is a research study to evaluate the usability of the Cogito digital therapeutics development platform. The Cogito platform is designed to allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with...

What is the current status of trial NCT07104396?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-07-02. Estimated completion is 2025-08-31.

What conditions does trial NCT07104396 study?

This clinical trial studies the following conditions: Substance Use Disorders (SUDs).

What interventions are being tested in trial NCT07104396?

The interventions under investigation include: Cogito digital therapeutics development platform (OTHER).

Who is sponsoring clinical trial NCT07104396?

This trial is sponsored by Square2 Systems, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07104396 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07104396, the US trial registry maintained by the National Library of Medicine. NCT07104396 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.